Melanoma News and Research

Latest Melanoma News and Research

Oral, Head & Neck Cancer Awareness Week: Mount Sinai experts to share tips on cancer prevention

Mouth and throat cancers are the fastest rising cancers today. They account for over 40,000 cases per year in the U.S. The American Cancer Society estimates that there will be 121,790 new cases of head and neck cancer diagnosed in 2015 and 14,240 deaths. These numbers include tongue cancer, throat cancers caused by the human papillomavirus or HPV, voice box cancer, melanoma of the face and thyroid cancers.

8 Apr 2015

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

St. Luke’s Cancer Center is a leader in offering clinical trials for patients with melanoma, the most unusual type of skin cancer and also the most deadly. Physicians such as Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology for St. Luke’s University Health Network and an internationally recognized melanoma specialist, are committed to bringing the most promising studies to the Lehigh Valley.

8 Apr 2015

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.

7 Apr 2015

CXCR3 molecule is key mediator of melanoma metastasis, shows research

In a unique partnership demonstrating excellence in "team science," Dartmouth investigators from Norris Cotton Cancer Center identified a role for the molecule CXCR3 (widely known to regulate the migration of immune cells) as a key mediator of melanoma metastasis.

7 Apr 2015

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis.

6 Apr 2015

Pyrexar Medical procures hyperthermia assets of BSD Medical, begins operations

Pyrexar Medical begins operations today after completing the acquisition of hyperthermia assets held by Perseon, formerly BSD Medical. This acquisition includes substantially all hyperthermia assets, products, services and related intellectual property.

3 Apr 2015

Future Science Group to provide free access to its peer-reviewed, cancer-focused journals

Future Science Group today announced that it will provide free access to three of its peer-reviewed, cancer-focused journals for the remainder of 2015.

3 Apr 2015

Novogen appoints PCG Advisory to manage investor-awareness program in the US

Novogen Ltd today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company's investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key relationships within the US investment community via their targeted outreach campaign.

2 Apr 2015

Researchers identify potential drug molecule that kills cancer cells

The average living cell needs communication skills: It must transmit a constant stream of messages quickly and efficiently from its outer walls to the inner nucleus, where most of the day-to-day decisions are made.

31 Mar 2015

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy.

30 Mar 2015

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint.

30 Mar 2015

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.

25 Mar 2015

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.

23 Mar 2015

Discovery may lead to new potential treatment for drug-resistant melanoma

In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.

23 Mar 2015

New triple combination therapy shows promise in controlling advanced melanoma

Results of a new study by UCLA researchers has found that a groundbreaking new triple combination therapy shows promising signs of more effectively controlling advanced melanoma than previous BRAF + MEK inhibitor or BRAF inhibitor + immunotherapy combos alone, and with increased immune response and fewer side effects.

20 Mar 2015

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA.

19 Mar 2015

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

The Ben May Department for Cancer Research at the University of Chicago will hold a day-long symposium on cancer immunotherapy for physicians and researchers.

18 Mar 2015

Two American scientists receive Paul Ehrlich and Ludwig Darmstaedter Prize

Two American scientists, James P. Allison and Carl H. June, will today receive the Paul Ehrlich and Ludwig Darmstaedter Prize in the Paulskirche in Frankfurt. Both give the patient's own immune system the lasting ability to fight cancer, Allison against late stage melanoma, June against leukemia.

16 Mar 2015

Combination of anti-Nodal and DTIC therapy can produce anti-cancer effects

Metastatic melanoma is the leading cause of skin cancer deaths in the United States; once melanoma has spread (metastasized), life expectancy for patients can be dramatically shortened.

13 Mar 2015

Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent diagnostic accuracy. Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States.

6 Mar 2015

Melanoma News and Research

Latest Melanoma News and Research

Oral, Head & Neck Cancer Awareness Week: Mount Sinai experts to share tips on cancer prevention

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

CXCR3 molecule is key mediator of melanoma metastasis, shows research

Personalized cancer vaccines can be used to marshal powerful immune response

Pyrexar Medical procures hyperthermia assets of BSD Medical, begins operations

Future Science Group to provide free access to its peer-reviewed, cancer-focused journals

Novogen appoints PCG Advisory to manage investor-awareness program in the US

Researchers identify potential drug molecule that kills cancer cells

Hospira announces availability of INFLECTRA (infliximab) in Canada

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Personalized gene therapy to fight against cancer

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Discovery may lead to new potential treatment for drug-resistant melanoma

New triple combination therapy shows promise in controlling advanced melanoma

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

Two American scientists receive Paul Ehrlich and Ludwig Darmstaedter Prize

Combination of anti-Nodal and DTIC therapy can produce anti-cancer effects

Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Melanoma News and Research

Latest Melanoma News and Research

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in